Brevan Howard Capital Management’s Myriad Genetics MYGN Stock Holding History

Brevan Howard Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104K	Sell	18,144 -3,189	-15%	-$14.5K	﹤0.01%	1985
2026 Q1	$96K	Buy	+21,333	New	+$111K	﹤0.01%	2031
2025 Q4	–	Sell	-21,900	Closed	-$158K	–	2125
2025 Q3	$158K	Buy	+21,900	New	+$130K	﹤0.01%	1802
2024 Q4	–	Sell	-16,965	Closed	-$465K	–	1298
2024 Q3	$465K	Buy	16,965 +2,349	+16%	+$63.6K	﹤0.01%	701
2024 Q2	$358K	Buy	+14,616	New	+$321K	﹤0.01%	718

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's MYGN Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Myriad Genetics (MYGN) stake by 15% in Q2 2026, selling an estimated $14.5K and leaving 18,144 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1985.

Brevan Howard Capital Management first reported a position in MYGN in Q2 2024 and has held it in 5 quarters since. The position peaked at $465K in Q3 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Brevan Howard Capital Management held 18,144 shares of Myriad Genetics worth $104K as of Q2 2026.
Brevan Howard Capital Management sold 3,189 Myriad Genetics shares in Q2 2026, an estimated $14.5K.
Myriad Genetics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1985 holding.
Brevan Howard Capital Management first reported a position in Myriad Genetics in Q2 2024 and has held it in 5 quarters since.
Brevan Howard Capital Management's Myriad Genetics position peaked at $465K in Q3 2024.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.